Abstract
Receptor tyrosine kinases are a group of molecules that can enhance cellular proliferation, cell motility and migration, and eventual metastasis. c-Met receptor tyrosine kinase has a significant biological and biochemical effect on cancer cells, and appears to be an important therapeutic target. In many cancers, c-Met (which can be activated by its ligand hepatocyte growth factor, HGF) can be overexpressed, activated, amplified, and/or mutated. The mutations of c-Met had initially been described in the tyrosine kinase domain, and we have described them in other “hot-spots” such as the juxtamembrane and semaphorin domains. Targeting c-Met has been very fruitful pre-clinically, and currently, there are several clinical trials for advanced cancers. Described in this review are some of the biological and biochemical aspects of c-Met, and detailed are a number of therapeutic strategies. With our understanding of c-Met biology and role in cancer, we should be able to arrive at a unique strategy to eradicate cancers in which c-Met plays a significant role.
Keywords: Hepatocyte growth factor, c-Met receptor tyrosine kinase, RTK catalytic activity, mTOR pathway, XL184
Reviews on Recent Clinical Trials
Title: Review of Clinic Trials: Agents Targeting c-Met
Volume: 2 Issue: 2
Author(s): Oyewale Abidoye, Nadh Murukurthy and Ravi Salgia
Affiliation:
Keywords: Hepatocyte growth factor, c-Met receptor tyrosine kinase, RTK catalytic activity, mTOR pathway, XL184
Abstract: Receptor tyrosine kinases are a group of molecules that can enhance cellular proliferation, cell motility and migration, and eventual metastasis. c-Met receptor tyrosine kinase has a significant biological and biochemical effect on cancer cells, and appears to be an important therapeutic target. In many cancers, c-Met (which can be activated by its ligand hepatocyte growth factor, HGF) can be overexpressed, activated, amplified, and/or mutated. The mutations of c-Met had initially been described in the tyrosine kinase domain, and we have described them in other “hot-spots” such as the juxtamembrane and semaphorin domains. Targeting c-Met has been very fruitful pre-clinically, and currently, there are several clinical trials for advanced cancers. Described in this review are some of the biological and biochemical aspects of c-Met, and detailed are a number of therapeutic strategies. With our understanding of c-Met biology and role in cancer, we should be able to arrive at a unique strategy to eradicate cancers in which c-Met plays a significant role.
Export Options
About this article
Cite this article as:
Abidoye Oyewale, Murukurthy Nadh and Salgia Ravi, Review of Clinic Trials: Agents Targeting c-Met, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599357
DOI https://dx.doi.org/10.2174/157488707780599357 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Cancer and Stem Cells
Current Cancer Therapy Reviews Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Progress in Developing Amphiphilic Cyclodextrin-Based Nanodevices for Drug Delivery
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Nongenomic Effects of Thyroid Hormones in Central Nervous System and Skeletal Muscle (Guest Editor: Sandra Incerpi)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews